Paris

• Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD). Ended recruitment
  2022-501250-12-01 7 2023-03-17 Inherited retinal dystrophies
• CAPTIRALL _ Combination of an Anti-PD1 antibody with CART cells Reinfusion in children, adolescents and young adults with Acute Lymphoblasti … Ended recruitment
  2024-514345-11-00 9 2023-03-15 children, adolescents and young adults with Acute Lymphoblastic Leukem
• A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Un … Ended recruitment
  2023-505211-21-00 4 2023-03-10 Previously untreated locally advanced or metastatic non-small cell lun
• PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien … Ended recruitment
  2022-501217-31-00 10 2023-03-09 Hepatocellular carcinoma
• Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized tr … Ended recruitment
  2022-501179-23-00 6 2023-03-08 atopic dermatitis
• A Study to Assess Safety, Tolerability and Efficacy of Garetosmab versus Placebo Administered Intravenously (IV) in Adult Participants With … Ended recruitment
  2023-508350-26-00 5 2023-03-02 Fibrodysplasia Ossificans Progressiva
• A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy Ended recruitment
  2024-512785-33-00 10 2023-03-01 Active Idiopathic Inflammatory Myopathy (IIM)
• A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended recruitment
  2022-500138-27-01 5 2023-02-28 Multiple Myeloma
• An Open-Label Phase 1/2 Trial to Evaluate the Safety, Tolerability, and Efficacy of MORAb 202 in Subjects with Selected Tumor Types. Ended recruitment
  2023-506868-14-00 9 2023-02-28 Solid tumors in 4 tumor types: platinum resistant ovarian cancer, trip
• REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended recruitment
  2023-506924-94-00 5 2023-02-28 Cardiovascular disease
• An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). Ended recruitment
  2023-510081-27-00 9 2023-02-28 Systemic Lupus Erythematosus.
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended recruitment
  2022-501901-10-00 6 2023-02-06 Chronic Hepatitis D Infection
• EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended recruitment
  2023-504832-16-00 4 2023-01-24 DIFFUSE LARGE B CELL LYMPHOMA
• An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr … Ended recruitment
  2024-510818-33-00 5 2023-01-24 Chronic Spontaneous Urticaria
• A clinical study of a virus transferring the gene for human Ornithine Transcarbamylase (OTC) in patients 12 years of age and older with late … Ended recruitment
  2024-514337-38-00 5 2023-01-24 Late-onset Ornithine transcarbamylase (OTC) deficiency
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• Efficacy and Safety Study of Nipocalimab for Adults with Active Inflammatory Myopathies Ended recruitment
  2023-505314-20-00 4 2023-01-20 Active Idiopathic Inflammatory Myopathies (IIM)
• This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics … Ended recruitment
  2023-510061-10-00 3 2023-01-09 Clear cell renal cell carcinoma (ccRCC, first-, second- and third-line
• Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended recruitment
  2024-512915-33-00 5 2022-12-22 Metastatic Colorectal Cancer
• Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has … Ended recruitment
  2024-514644-93-00 5 2022-12-09 Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
• Study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 3 Ended recruitment
  2024-514381-39-00 5 2022-12-08 Gaucher's disease type III
• A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. Ended recruitment
  2023-504867-18-00 5 2022-12-05 Patients with Paroxysmal Nocturnal Hemoglobinuria

Showing 1,489–1,512 of 2,286 trials